LifeStance Health Group, Inc.

Profitability for 1 year: +24.61%
Dividend yield: 0%
Sector: Healthcare

Company Analysis LifeStance Health Group, Inc.

Download the report: word Word pdf PDF

1. Summary

Advantages

  • The stock's return over the last year (24.61%) is higher than the sector average (-45.46%).
  • Current debt level 8.81% is below 100% and has decreased over 5 years from 23.1%.

Disadvantages

  • Price (6.33 $) is higher than fair price (0.39 $)
  • Dividends (0%) are below the sector average (0.5%).
  • The company's current efficiency (ROE=0.64%) is lower than the sector average (ROE=95.3%)

Similar companies

Illumina

ImmunoGen

ABIOMED

Alexion

2. Share price and performance

2.1. Share price

2.3. Market efficiency

LifeStance Health Group, Inc. Healthcare Index
7 days -8.4% -13.1% -1.3%
90 days -14.2% -11.7% -3.4%
1 year 24.6% -45.5% 21.7%

LFST vs Sector: LifeStance Health Group, Inc. has outperformed the "Healthcare" sector by 70.07% over the past year.

LFST vs Market: LifeStance Health Group, Inc. has outperformed the market by 2.94% over the past year.

Stable price: LFST is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.

Long period: LFST with weekly volatility of 0.47% over the past year.

3. Summary of the report

3.1. General

P/E: 256.23
P/S: 1.74

3.2. Revenue

EPS 0.0247
ROE 0.64%
ROA 0.44%
ROIC -21.54%
Ebitda margin 5.53%

5. Fundamental Analysis

5.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Above fair price: The current price (6.33 $) is higher than the fair price (0.39 $).

Price is higher than fair: The current price (6.33 $) is 93.8% higher than the fair price.

5.2. P/E

P/E vs Sector: The company's P/E (256.23) is higher than that of the sector as a whole (28.18).

P/E vs Market: The company's P/E (256.23) is higher than that of the market as a whole (-87.91).

5.2.1 P/E Similar companies

5.3. P/BV

P/BV vs Sector: The company's P/BV (1.63) is lower than that of the sector as a whole (238.73).

P/BV vs Market: The company's P/BV (1.63) is lower than that of the market as a whole (81.51).

5.3.1 P/BV Similar companies

5.5. P/S

P/S vs Sector: The company's P/S indicator (1.74) is lower than that of the sector as a whole (128.13).

P/S vs Market: The company's P/S indicator (1.74) is lower than that of the market as a whole (116.07).

5.5.1 P/S Similar companies

5.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (34.71) is higher than that of the sector as a whole (-20.87).

EV/Ebitda vs Market: The company's EV/Ebitda (34.71) is higher than that of the market as a whole (-78.96).

6. Profitability

6.1. Profitability and revenue

6.2. Earnings per share - EPS

6.3. Past profitability Net Income

Yield Trend: Negative and has fallen by -20.63% over the last 5 years.

Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-20.63%).

Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-24.38%).

6.4. ROE

ROE vs Sector: The company's ROE (0.64%) is lower than that of the sector as a whole (95.3%).

ROE vs Market: The company's ROE (0.64%) is lower than that of the market as a whole (22.94%).

6.6. ROA

ROA vs Sector: The company's ROA (0.44%) is higher than that of the sector as a whole (-4.47%).

ROA vs Market: The company's ROA (0.44%) is lower than that of the market as a whole (3.9%).

6.6. ROIC

ROIC vs Sector: The company's ROIC (-21.54%) is lower than that of the sector as a whole (-0.11%).

ROIC vs Market: The company's ROIC (-21.54%) is lower than that of the market as a whole (8.79%).

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

7. Finance

7.1. Assets and debt

Debt level: (8.81%) is quite low in relation to assets.

Debt reduction: over 5 years, the debt has decreased from 23.1% to 8.81%.

Excess of debt: The debt is not covered by net income, percentage 2008.66%.

7.2. Profit growth and share price

8. Dividends

8.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0% is below the average for the sector '0.5%.

8.2. Stability and increase in payments

Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

8.3. Payout percentage

Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

9. Insider trades

9.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

9.2. Latest transactions

Transaction date Insider Type Price Volume Quantity
18.12.2025 Bessler Robert
Director
Purchase 7 4 509 6 442
18.08.2025 SUMMIT INVESTORS GE IX/VC IV (
Owner
Purchase 5.41 20 336 3 759
18.08.2025 SUMMIT INVESTORS GE IX-VC IV,
Owner
Purchase 5.41 194 425 35 938
16.06.2025 Ramtekkar Ujjwal
Officer
Purchase 5.17 49 213 9 519
09.04.2025 Bessler Robert
Director
Purchase 7.01 34 349 4 900